Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Francesco Marchesi, Jon Salmanton-García*, Caterina Buquicchio, Federico Itri, Caroline Besson, Julio Dávila-Valls, Sonia Martín-Pérez, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Mariarita Sciume, Jorge Labrador, Raul Cordoba, Alberto López-García, Nicola S. Fracchiolla, Francesca Farina, Emanuele Ammatuna, Antonella Cingolani, Daniel García-BordalloStefanie K. Gräfe, Yavuz M. Bilgin, Michelina Dargenio, Tomás José González-López, Anna Guidetti, Tobias Lahmer, Esperanza Lavilla-Rubira, Gustavo Adolfo Méndez, Lucia Prezioso, Martin Schönlein, Jaap Van Doesum, Dominik Wolf, Ditte Stampe Hersby, Ferenc Magyari, Jens Van Praet, Verena Petzer, Carlo Tascini, Iker Falces-Romero, Andreas Glenthøj, Oliver A. Cornely, Livio Pagano

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    15 Citaten (Scopus)
    11 Downloads (Pure)


    Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

    Originele taal-2English
    TijdschriftJournal of Hematology and Oncology
    Nummer van het tijdschrift1
    StatusPublished - dec.-2023

    Citeer dit